Little is known, however, about DC subsets in human chronic kidney disease, with previous studies restricted to a limited set of pathologies and to using immunohistochemical methods. In this study, we developed novel protocols for extracting renal DC subsets from diseased human kidneys and identified, enumerated, and phenotyped them by multicolor flow cytometry. We detected significantly greater numbers of total DCs as well as CD141 hi and CD1c ϩ myeloid DC (mDCs) subsets in diseased biopsies with interstitial fibrosis than diseased biopsies without fibrosis or healthy kidney tissue. In contrast, plasmacytoid DC numbers were significantly higher in the fibrotic group compared with healthy tissue only. Numbers of all DC subsets correlated with loss of kidney function, recorded as estimated glomerular filtration rate. CD141 hi DCs expressed C-type lectin domain family 9 member A (CLEC9A), whereas the majority of CD1c ϩ DCs lacked the expression of CD1a and DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN), suggesting these mDC subsets may be circulating CD141 hi and CD1c ϩ blood DCs infiltrating kidney tissue. Our analysis revealed CLEC9A ϩ and CD1c ϩ cells were restricted to the tubulointerstitium. Notably, DC expression of the costimulatory and maturation molecule CD86 was significantly increased in both diseased cohorts compared with healthy tissue. Transforming growth factor-␤ levels in dissociated tissue supernatants were significantly elevated in diseased biopsies with fibrosis compared with nonfibrotic biopsies, with mDCs identified as a major source of this profibrotic cytokine. Collectively, our data indicate that activated mDC subsets, likely recruited into the tubulointerstitium, are positioned to play a role in the development of fibrosis and, thus, progression to chronic kidney disease. chronic kidney disease; human dendritic cells; interstitial fibrosis; transforming growth factor-␤; tubulointerstitium DENDRITIC CELLS (DCs) are bone marrow-derived antigen-presenting cells that play critical roles in the initiation of immune responses. In response to danger signals, the rate of DC migration to sites of injury is increased, and the triggering and maturation of DC can lead to the upregulation of costimulatory molecules, production of inflammatory cytokines, and priming of T cell responses.
Human DCs are classically defined as CD45 ϩ leukocytes that lack other leukocyte lineage (lin) markers and express high levels of major histocompatibility complex class II [human leukocyte antigen (HLA)-DR] (lin Ϫ HLA-DR ϩ ) (16) . Human DCs are a heterogeneous population of cells, with subsetspecific functional specializations emerging (14, 15, 17, 31) . These can be broadly categorized into, first, blood and lymphoid organ-resident DCs comprising type I interferon-producing CD11c
plasmacytoid DCs (pDCs) and CD11c ϩ myeloid DCs (mDCs) (24) . mDCs are further delineated into a CD141 (BDCA-3) hi C-type lectin domain family 9 member A (CLEC9A) ϩ subset with a superior capacity to cross-present exogenous antigen to CD8 ϩ T cells (14) and a CD1c (BDCA-1) ϩ population (16 (20) , of which the latter subset is closely linked to human monocyte/macrophage populations and has weak allostimulatory capacity (8, 20, 39) . Finally, inflammatory DCs rapidly differentiate from peripheral blood monocytes in response to inflammation (38) .
The role of DCs in the initiation and progression of acute and chronic kidney diseases (CKDs) has been studied in different murine models (11, 22, 42) . Interestingly, while mouse DCs have a protective role in acute immune-mediated kidney disease (32), they acquire a pathogenic proinflammatory functionality in murine models of CKD, e.g., lupus nephritis (2, 12, 43) , T cell-mediated glomerular injury (9) , and chronic crescentic glomerulonephritis (GN) (10) . However, the identification and function of human kidney DCs remain poorly defined.
The initial identification and enumeration of DC populations in diseased human kidney biopsies have been made, although primarily using immunohistochemistry (IHC). This methodology limits the ability to combine the multiple markers necessary to unequivocally define specific DC populations and determine absolute DC subset counts. In these IHC studies, DC were largely localized to the tubulointerstitium (3 , and CD1c ϩ cells, suggesting a pathogenic role for recruited blood DC populations in this disease setting. However, single staining for these antigens is inadequate to directly identify DC subsets given the expression of these markers on numerous leukocyte and nonhematopoietic cell types in peripheral tissues. Clearly a progression to multiparameter staining methodologies is required to more accurately detect, phenotype, and quantify DC subsets in human kidney disease.
Here, we developed novel protocols for obtaining single cell suspensions from biopsies from a wide range of human kidney diseases to allow the identification and enumeration of DC subsets via 10-color flow cytometry. We demonstrate that diseased biopsies with interstitial fibrosis, the pathological hallmark of CKD, have significantly elevated numbers of tubulointerstitial CD141 hi CLEC9A
ϩ mDCs and CD1c ϩ mDCs compared with nonfibrotic biopsies, with mDC identified as a key source of the fibrogenic growth factor transforming growth factor (TGF)-␤. Fresh biopsies were taken with a 16-gauge biopsy needle (Biopsybell, Mirandola, Italy) and immediately divided for 1) tissue dissociation (1-5 mm of a core biopsy), 2) freezing in Tissue-Tek OCT compound (Sakura, Torrance, CA) for IHC analysis, and 3) fixation in formalin to assess the levels of interstitial fibrosis/tubular atrophy by renal histopathologists blinded to the experimental results. For the assessment of renal interstitial fibrosis, formalin-fixed 4-m sections were stained with Masson's trichrome, and the proportion of bluestained fibrotic area in the cortex of each section was graded semiquantitatively. The average percent fibrosis for each biopsy was based on the assessment of 20 slides. For the purposes of this study, biopsies displaying Ն5% interstitial fibrosis were deemed fibrotic, based on the Banff 97 working classification of renal pathology (30) . Kidney function [estimated glomerular filtration rate (eGFR)] was calculated using the MDRD method by AUSLAB (Queensland Health), and the degree of proteinuria was defined using a urine protein-to-creatinine ratio (uPCR).
MATERIALS AND METHODS

Tissue
Tissue dissociation. Samples were enzymatically digested with 1 mg/ml collagenase P (Roche, Mannheim, Germany) in the presence of 20 g/ml DNase I (Roche) (250-l volume) for 15 min. The supernatant from this initial dissociation step was collected for the analysis of cytokine levels. Dissociated tissue was then further digested with 10 g/ml trypsin-4 g/ml EDTA (Invitrogen, Grand Island, NY) (500-l volume) for 10 min. Flow-Count fluorospheres (Beckman Coulter, Brea, CA) were used for the direct determination of absolute counts following the manufacturer's recommendations. Briefly, target cell concentrations (in cells/l) were calculated as follows: total number of target cells counted/total number of fluorospheres counted ϫ flow-count fluorosphere concentration. This value was then multiplied by the total sample volume to obtain absolute counts for each target cell population. Total cell counts were then normalized to cell numbers per cm 3 of tissue, in which the volume of renal tissue was calculated as follows: r 2 ϫ length of biopsy tissue, where the radius (r) of a 16-gauge biopsy is 0.8 mm. Cell acquisition was performed on an LSR Fortessa (BD), and data were analyzed with FlowJo software (TreeStar, Ashland, OR). Validation of this methodology demonstrated minimal variation in DC numbers when multiple biopsies from one healthy kidney tissue were sampled (data not shown).
IHC staining. Frozen 6-m tissue sections were fixed with 25% ethanol-75% acetone at room temperature for 5 min and blocked with an Avidin/Biotin Blocking kit (Vector Laboratories, Burlingame, CA) and Background Sniper Blocking Reagent (Biocare Medical, Concord, CA). Sections were probed with biotinylated anti-CLEC9A (clone 8F9, Miltenyi Biotec, Auburn, CA), biotinylated anti-CD1c (clone L161, Biolegend, San Diego, CA), or isotype-matched control antibodies at room temperature overnight. Endogenous peroxidase activity was blocked with 1% H 2O2 for 5 min followed by an incubation with horseradish peroxidase-conjugated streptavidin (Invitrogen) for 1 h. Peroxidase activity was developed with diaminobenzidine substrate for 10 min. Sections were lightly counterstained with hematoxylin and eosin and mounted using DPX Mounting Media (Leica Microsystems, Heidelberg, Germany).
Cytokine detection. Dissociation supernatants were harvested, and levels of IL-1␤, IL-6, IL-8, IL-10, IL-12p70, and TNF-␣ were determined using Flow Cytometric Bead Arrays (BD, San Jose, CA) according to the manufacturer's instructions. TGF-␤ was detected in HCl-pretreated samples using the Quantikine Human TGF-␤ 1 Immunoassay (R&D Systems, Minneapolis, MN) following the manufacturer's recommendations. Cytokine values were normalized to the volume of 5 mm of renal core biopsy tissue. HLA, human leukocyte antigen; CXCR1, chemokine (C-X-C motif) receptor 1; CLEC9A, C-type lectin domain family 9 member A; LAP (TGF-␤1), transforming growth factor (TGF)-␤1 latency-associated peptide. *Lineage mix.
Statistics. Comparisons between two groups were performed using a two-tailed Mann-Whitney test, and multiple comparisons were performed using a Kruskal-Wallis test with Dunn's posttest. Statistical tests were performed using Prism 5.0 analysis software (GraphPad Software, La Jolla, CA). P values of Յ0.05 were considered statistically significant.
RESULTS
Identification of DC subsets in healthy human kidney tissue.
Healthy cortical tissue was obtained from 14 donors (7 women and 7 men, mean age: 62 Ϯ 12 yr) and enzymatically digested to obtain single cells for flow cytometric analysis. We designed our flow cytometric gating strategy to identify leukocyte populations using healthy kidney tissue (Fig. 1A) . CD45
ϩ leukocytes were separated into granulocytes with a higher side scatter profile and mononuclear cells, which could be further divided into lin (CD3, CD14, CD19, CD20, CD34, and CD56)
ϩ HLA-DR Ϫ lymphocytes, lin ϩ HLA-DR ϩ monocytes, and DCs, identified for the first time in human kidney tissue as lin Ϫ HLA-DR ϩ cells. We identified and characterized DC subpopulations using a combination of surface antigens expressed on human blood and tissue-resident DCs. These were broadly categorized into CD11c Ϫ CD123 hi pDCs and CD11c ϩ mDCs, with the latter further divided into CD141 hi DCs and a more abundant CD1c ϩ DC subset (Fig. 1A) . Importantly, these surface molecules used to identify DC subsets in kidney tissue were resistant to proteolytic cleavage as confirmed by enzymatic digestion (with collagenase P and trypsin-EDTA) of peripheral blood mononuclear cells (data not shown).
Phenotypical analysis showed that CD141 hi DCs express lower HLA-DR and similar CD11c levels compared with CD1c ϩ DC (Fig. 1B) . Notably, CLEC9A was expressed selectively, but at low levels, by CD141 hi DCs. CD1a was only present on a proportion of CD1c ϩ DCs (Fig. 1B) , likely representing a migratory tissue DC population. Previous studies (36, 45) have used DC-SIGN to identify mDCs within kidney biopsies. However, consistent with its broader expression on cells of a monocyte/macrophage lineage (6), we observed DC-SIGN expression on only a small fraction of CD1c ϩ DCs (Fig. 1B) , with the majority of positive DC-SIGN staining within the monocyte gate (data not shown). Finally, CD141
hi and CD1c ϩ DCs displayed similar low expression of costimulatory molecule CD86 (Fig. 1B) . From these results, we conclude that DC populations previously identified in other nonlymphoid healthy tissue (skin, liver, and lung) (8, 39) are also present in healthy kidney tissue. 
An identical gating strategy to that used for healthy tissue was applied to identify leukocyte populations in diseased biopsies. We observed equivalent flow cytometric profiles in diseased biopsies as those shown in Fig. 1 for healthy kidney tissue (data not shown). The viability of CD45 ϩ leukocytes, based on flow analysis, was routinely Ͼ90% for both healthy and diseased kidney tissue (data not shown). Quantification with Flow-Count fluorospheres revealed a significant increase in total leukocytes in diseased biopsies with interstitial fibrosis compared with diseased biopsies without fibrosis and healthy kidney tissue (Fig. 2A) . Whereas granulocyte numbers were similar between groups, numbers of lymphocytes, monocytes, and DCs were significantly higher in the fibrosis cohort (Fig. 2,  B and C) . Notably, DC numbers were the most significantly different between groups. These results associate DCs with the development of renal interstitial fibrosis.
Diseased biopsies with interstitial fibrosis contain significantly elevated numbers of CD141
hi DCs and CD1c ϩ DCs. We next enumerated pDC and mDC subsets in healthy and diseased tissue. Whereas pDC numbers were significantly higher in fibrotic biopsies compared only with healthy tissue (Fig. 3A) , significantly elevated numbers of CD141 hi and CD1c ϩ DCs were detected in diseased biopsies with fibrosis compared with both diseased biopsies without fibrosis and healthy tissue (Fig. 3, B and  C) . Notably, as observed in healthy tissue, CLEC9A was selectively expressed, although at low levels, by CD141
hi DCs in diseased biopsies (data not shown). Of CD1c ϩ DCs, numbers of CD1a ϩ cells were similar between all three groups, consistent with their corresponding to migratory tissue DCs (Fig. 3D) , and DC-SIGN ϩ cells were significantly elevated in both disease groups compared with healthy tissue (Fig. 3E) .
The proportional representation of DC subsets within their parent lin Ϫ HLA-DR ϩ population was also assessed, with similar percentages of pDCs and CD141
hi DCs between healthy and diseased kidney tissue (Fig. 3F) . In contrast, diseased biopsies with fibrosis contained a significantly higher proportion of CD1c ϩ DCs, within which the percentages of both CD1a ϩ and DC-SIGN ϩ cells were lower, compared with diseased biopsies without fibrosis (Fig. 3F ). Based on current nomenclature, these CD1c ϩ CD1a Ϫ DC-SIGN Ϫ cells enriched in fibrotic biopsies likely represent CD1c ϩ blood DCs locally recruited from the circulation.
In addition to tissue pathology (interstitial fibrosis), DC counts were stratified based on kidney function (eGFR levels), the degree of proteinuria (uPCR), and primary diagnoses of patients. Numbers of DCs, pDCs, CD141
hi DCs, and CD1c ϩ DCs correlated significantly with loss of kidney function (Fig. 4, A-D) but not with proteinuria (data not shown). Significant associations with individual primary diagnoses could not be made due to the broad spectrum of diseases and, thus, low numbers of each disease sampled (data not shown). Broader grouping of biopsies into glomerular immune-mediated, glomerular nonimmune-mediated, and nonglomerular diseases revealed elevated numbers of DCs, pDCs, CD141
hi DCs, and CD1c ϩ DCs across all primary diagnosis groups, although the highest counts were detected in patients with nonglomerular diseases (Fig. 5, A-D) . Collectively, these data show that DC subset numbers and distribution are related to kidney pathogenesis and functional outcome. hi DCs, restricted to the tubulointerstitial compartment (Fig. 6, A and B) . Consistent with our flow cytometric analyses, a prominent accumulation of CD1c ϩ and CLEC9A ϩ cells was present in diseased biopsies with interstitial fibrosis compared with nonfibrotic biopsies. Notably, CD1c ϩ and CLEC9A ϩ cells predominantly localized to sites of tubulointerstitial injury, in particular inflammation and tubular atrophy (Fig. 6, A and B) , suggesting that these mDC subsets are positioned to participate in interstitial disease progression.
Elevated CD86 expression in diseased kidney biopsies. To compare the phenotypes of kidney DCs in healthy and diseased tissue, we assessed HLA-DR and CD86 expression levels using our flow cytometric methodology. Whereas HLA-DR expression on DCs was reduced in diseased biopsies with and without fibrosis compared with healthy tissue (Fig. 7A) , levels of CD86, a marker of DC maturation, were significantly elevated in both disease groups (Fig. 7B) . Similar results have been observed when diseased biopsies were grouped based on eGFR results (data not shown). These CD86 data suggest that the local environment within diseased kidneys direct DCs toward a more activated, pathogenic phenotype. 
Significantly elevated IL-8 in diseased biopsies with interstitial fibrosis.
The supernatant from dissociated tissue was also analyzed for cytokine levels. Proinflammatory IL-1␤ (Fig. 8A) and T helper 1-inducing IL-12p70 levels (Fig. 8B) were significantly higher in the supernatant of dissociated diseased biopsies compared with healthy tissue. TNF-␣, IL-6, and IL-10 were not detectable in either healthy or diseased groups (data not shown), whereas levels of chemo- kine IL-8 were higher, but not to significant levels, in diseased biopsies (Fig. 8C) . When cytokine levels were stratified on interstitial fibrosis, both IL-1␤ and IL-12p70 were nonsignificantly elevated in diseased biopsies with and without fibrosis compared with healthy tissue (data not shown). In contrast, IL-8 levels were significantly increased compared with healthy tissue in only those diseased biopsies with interstitial fibrosis (Fig. 9A) . IL-8 levels also correlated significantly with the loss of kidney function as determined by eGFR levels (Fig. 9B) . This cytokine signature is consistent with an inflammatory environment within fibrotic kidney biopsies. Notably, expression of the IL-8 receptor chemokine (C-X-C motif) receptor 1 (CXCR1) within fibrotic biopsies was detected using our novel flow cytometric methodology, identifying the highest CXCR1 expression on granulocytes, moderate expression on monocytes and DCs, and low CXCR1 levels on lymphocytes and a subpopulation of CD45 Ϫ cells (Fig. 9C) .
Significantly elevated TGF-␤ in diseased biopsies with interstitial fibrosis.
To examine the putative role of DCs in the development of interstitial fibrosis, we assessed the levels and source of profibrotic factor TGF-␤ within diseased renal biopsies. TGF-␤ levels were significantly elevated in diseased biopsies with interstitial fibrosis compared with nonfibrotic biopsies (Fig. 10A) . Levels of TGF-␤ also correlated with loss of kidney function, with the highest mean TGF-␤ in diseased biopsies from patients with stage IV-V CKD (Fig. 10B) . We next determined the source of this TGF-␤ within fibrotic biopsies by flow cytometry. The highest levels of TGF-␤ latency-associated peptide (LAP), a component of the TGF-␤ complex secreted by cells (25) , were detected on monocytes and DCs (Fig. 10C) . Notably, LAP (TGF-␤)-positive DCs Fig. 7. A and B: surface expression of HLA-DR (A) and CD86 (B) in healthy kidney tissue and diseased biopsies without (ϪFb) and with fibrosis (ϩFb). Left: values of mean fluorescence intensity (MFI) for individual donors. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 by Kruskal-Wallis test. Right: representative histograms of HLA-DR and CD86 expression on DCs from healthy kidney tissue and diseased biopsies without and with interstitial fibrosis compared with isotype. Fig. 8. A-C: IL-1␤ (A), IL-12p70 (B) , and IL-8 (C) levels in healthy and diseased kidney tissue. Each symbol represents an individual donor. *P Ͻ 0.05 and **P Ͻ 0.01 by Mann-Whitney test.
were predominantly CD11c ϩ mDCs (data not shown). Lowlevel expression of this form of TGF-␤ was also detected on granulocytes and a subpopulation of CD45 Ϫ cells (Fig. 10C) . Collectively, these results further associate mDCs with the development of renal interstitial fibrosis through the production of TGF-␤.
DISCUSSION
DCs are established key players in kidney diseases. In this study, we developed novel methods for the extraction of adequate numbers of DC subsets from healthy and diseased human cortical biopsy tissue for multicolor phenotypic and quantitative characterization. Here, we demonstrate, for the first time, irrespective of primary diagnosis, an association between absolute numbers of tubulointerstitial CD141 hi CLEC9A
ϩ DCs and CD1c ϩ DCs with both the tissue pathology of CKD (presence of interstitial fibrosis) and loss of kidney function (decreased eGFR levels). Notably, we identified CD11c ϩ mDCs as a major source of TGF-␤ in fibrotic biopsies. Collectively, these data suggest that activated mDC subsets are of profound importance in interstitial fibrosis and thus CKD.
Our study is the first detailed analysis of CD141 hi CLEC9A ϩ DCs, the main human cross-presenting mDC population (14) , in kidney tissue. CD141 ϩ cells have been previously shown to infiltrate the renal tubulointerstitium in patients with lupus nephritis (5). However, as highlighted in our study (Fig. 1B) and by Segura et al. (39) , CD141 is also expressed, although at lower levels, on CD1c ϩ DCs and CD14 ϩ DCs in human tissues. In contrast, CLEC9A is selectively expressed by CD141
hi DCs in human blood, bone marrow, lymph nodes, spleen, tonsils, skin, and lungs (8, 14, 29, 39 ) and now, as we report, in kidney tissue. In our hands, CLEC9A is expressed on CD141
hi kidney DCs at reduced levels compared with immature CD141 hi blood DCs (data not shown). This lower CLEC9A expression compared with CD141 hi blood DCs has also been reported in human CD141 hi skin DCs (8) and may be the result of a maturation-induced downregulation within peripheral tissues, as demonstrated upon in vitro maturation of immature CD141 hi blood DCs (34). Interestingly, recent transcriptional profiling clustered CD141 hi DCs from human skin and blood with each other (8) , suggesting that CD141 hi blood DCs may in fact be a precursor of their tissue DC counterpart. It is thus tempting to suggest that the CD141 hi kidney DC population identified in our study may also display functional homology to these cross-presenting DCs. This hypothesis is supported by the localization of CLEC9A ϩ cells within the tubulointerstitium in close proximity to lymphocytic infiltrates (Fig. 6B) . Further investigation is now required to establish if, upon injury, CD141
hi DCs in the kidney become immunogenic and cross-present normally immunologically inert self-antigens, such as albumin (23) , to trigger pathogenic CD8 ϩ T cell responses. CD1c ϩ DCs were the most prevalent kidney DC population identified in this study. CD1c
ϩ DCs enriched in fibrotic biopsies were primarily negative for CD1a and DC-SIGN, indicating that these DC likely correspond to recruited CD1c ϩ blood DCs and not to local proliferation of resident DCs, as has been suggested in recent murine studies (18, 33) . This concept is consistent with a previous study (5) that associated a reduction in circulating CD1c ϩ blood DCs with a marked tubulointerstitial infiltration of CD1c ϩ cells in patients with lupus nephritis. However, the CD1c ϩ cell population is heterogeneous. As reported in the human liver (8), our study also demonstrates that a small proportion of CD1c ϩ DCs in kidney tissue express CD1a. Furthermore, the majority of these CD1c ϩ CD1a ϩ kidney DCs did not express DC-SIGN, suggesting that these cells are migratory tissue DCs that will include Langerhans cells and interstitial CD1a
ϩ DCs. In support of this proposition, we detected similar numbers of CD1c ϩ CD1a ϩ DCs in healthy and diseased kidney tissue. This is in agreement with a previous report (36) of equally rare langerin ϩ cells in both healthy kidney tissue and diseased biopsies from patients with GN.
Consistent with previous IHC-based data in patients with GN (36) , and in particular lupus nephritis (5), we detected a considerable increase in pDCs in diseased biopsies using our novel flow-based approach. However, unlike CD141 hi DC and CD1c ϩ DC subsets, pDC numbers did not significantly differ between diseased biopsies with and without fibrosis, suggesting that this DC subset may play only a minor role in the development of interstitial fibrosis.
Although the most significant increases in absolute numbers were observed within the DC compartment, our data also show significantly elevated numbers of lymphocytes and monocytes within diseased biopsies with fibrosis. We included CD14 within our lineage panel to eliminate monocytes from the DC gate. The addition of CD14 to our lineage mix may have inflated monocyte numbers by incorporating both macrophagelike interstitial CD14 (Fig. 3E) . However, numbers of CD1c ϩ DC-SIGN ϩ DC did not significantly differ between fibrotic and nonfibrotic diseased biopsies, suggesting that this population may have a minimal role in the progression of CKD. These DCs may be analogous to previously reported CD1c ϩ DC-SIGN ϩ cells identified in the cortex of healthy kidneys (45) and attributed to a monocyte-derived DC population (27) . DC expression of CD86 was low in healthy kidney tissue, indicative of an immature DC phenotype in well-preserved renal tissue. In contrast, CD86 levels on DCs from diseased biopsies were significantly increased, consistent with local stimuli within the interstitium of diseased kidneys driving DCs toward a mature activation stage. This concept concurs with the results of Segerer et al. (36) showing low levels of DClysosome-associated membrane glycoprotein (LAMP) mRNA, an alternative marker of mature DCs, in healthy kidney tissue, with a significant tubulointerstitial increase in DC-LAMP expression in human proliferative GN. Similarly, pathogenic kidney DCs with increased CD86 expression and IL-12 production have been identified in a mouse model of CKD (10) .
Cytokine-mediated inflammation has been implicated in the pathogenesis of CKD. This inflammatory cascade is initiated by injured or activated kidney cells and/or infiltrating leukocytes producing proinflammatory chemokines and cytokines, which, in turn, recruit and activate additional leukocytes (including DCs) within sites of injury (1) . In line with this concept, proinflammatory cytokines IL-1␤ and IL-12, known to contribute to renal fibrosis (13, 19, 44) and produced by pathogenic kidney DCs in mouse models (10, 28) , were detected at significantly elevated levels in diseased biopsies compared with healthy tissue. Furthermore, levels of chemoattractant IL-8 were shown to closely correlate with numbers of infiltrating leukocytes (lymphocytes, monocytes, and DCs), presence of interstitial fibrosis, and loss of renal function in diseased biopsies. IL-8 expression in human kidney tissue has been detected in multiple renal compartments, including the glomerular tuft, tubular epithelial cells, endothelial cells, and some interstitial cells (26) , whereas its corresponding receptor CXCR1 has been shown by IHC to be expressed on infiltrating inflammatory cells (predominantly granulocytes) and intrinsic renal cells (arterial smooth muscle cells and endothelial cells of peritubular capillaries) (37) . We examined the expression of CXCR1 within diseased renal biopsies using, for the first time, flow cytometric techniques. In line with the results of this previous IHC study, the highest CXCR1 expression was detected on granulocytes. However, CXCR1 was also identified on infiltrating monocytes and DCs, with low-level expression on lymphocytes and a subpopulation of CD45 Ϫ intrinsic renal cells. Further research is required to investigate the role of the IL-8-CXCR1 axis in the recruitment of leukocytes, particularly DCs, in CKD.
TGF-␤ is the principal fibrogenic growth factor implicated in the pathogenesis of renal scarring (46, 47) . Consistent with this concept, we detected significantly increased levels of TGF-␤ in fibrotic tissue (Fig. 10A ). An IHC-based study (7) of patients with glomerular disease reported TGF-␤ protein expression within tubular epithelial and interstitial cells. In addition, the intensity of tubulointerstitial TGF-␤ expression correlated positively with the degree of interstitial inflammation and fibrosis (7), suggesting a potential role for interstitial TGF-␤-producing inflammatory cells in potentiating fibrosis. Our present study extends these observations by identifying monocytes and mDCs as the highest expressors of TGF-␤ on a per cell basis within fibrotic renal tissue (Fig. 10C) . Notably, whereas monocytes/macrophages are present in both the tubulointerstitial and glomerular compartments (35) , DCs predominantly infiltrate the tubulointerstitium, further highlighting a potentially unique and pivotal role for mDCs in CKD progression.
Based on our results, we propose that circulating CD141 hi CLEC9A ϩ and CD1c ϩ DC subsets are recruited into the interstitium in response to injury and receive activation signals to acquire a pathogenic, proinflammatory functionality critical in the development of interstitial fibrosis and subsequent loss of renal function in CKD. In conclusion, our present investigation provides novel tools for the enumeration and phenotyping of human kidney DC subsets that will allow us to better understand their functional roles in the kidney. The tools are readily translatable to human diagnostics of the future, where DCs may become prognostic markers of the progressive loss of kidney function.
